Rainbow Rare Earths Phalaborwa project shaping up to be one of the lowest cost producers globally. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Some notable selling today. I am at a loss to understand why, but your last post may offer an explanation.
Most of the buys are automatic trades, so someone also accumulating.
I have added some more today and I now on the limit of what I will hold for one share. I cannot see anything concerning and I expect to see a rise into the results, which we now are good.
Some forward guidance for 2022 would help, just allay fears that this EKF is not dependant on Covid for revenues.
Its altogether a strange market at the moment,
vig - does seem to be constant downward pressure at the moment - but on relatively light volume. Its possible people are just taking profits - its had a great rise in the last 2 years from 30p, and whilst we are at an 18 month low sellers who had held for a while will still be able to make a decent return in a choppy market. EFK normally reports end march so no worries there. Would be a good time to see some director support - although we are just heading into a closed period prior to the EOY results - which are both 'strong' and 'ahead of already upgraded market expectations'. Ones things for sure - diagnostic testing is a huge growth sector - and we are in the right place to develop in this space alongside the scaling of our contract manufacturing business. SB
More automatic sells showing up, but one large 100k buy this afternoon.
No real idea on who is selling, but the share price seems to be pegged back at circa 63p.
Release of 2021 results I understand may not be until March.
Yes, I was in SXX and thought that was pretty solid. That was a painful experience. . I think Anglo American got a bargain! and I guess the government were not focused on the shareholders as the jobs and project were assured by AA.
Re EKF it looks clear someone is offloading shares, so the price is drifting down.
I will post on here if I can get any information to throw light on this. Vig.
Thanks - didn't see the Singer note - broker notes don't seem to get updated here. Price is at an 18 month low - should move up towards actual results expected late March 22. Unless the market knows something we don't - like an acquisition and fundraise. Good timing on your move into cash last week! I note you were also in SXX - not a particularly pleasant investment experience for me - just didn't see that outcome coming and still gets me that the government did not provide more support to help unlock the debt package. SB
I think you could be right about people making assumptions that EKF are reliant on Covid ( like ODX, GDR etc) and thinking they will take a hit from related revenues in 2022. I personally don't think so as they quite well diversified.
I was selling up a lot of holdings last week, but decided to hang on to EKF. You can never be completely sure in this game as sentiment plays as big a part as fundamentals at times.
FYI Research note from Singer Capital Markets yesterday was pretty bullish with conservative target of 86p
Agreed - does appear a disappointing reaction to a good update. Another issue may be the perception that the covid trading side of the business may not be as strong moving forward and as such growth will focus on core business which has performed well with a 13% increase but that's perhaps less than the market expected - albeit ahead of previous projections. That said - the business does refer to diversification into non-covid testing and the ADL purchase will build on that capacity. As you say - don't see any specific risk here other than people moving into cash and the global market issues. Don't think we will be at this price for too long. SB
My opinion:
Someone is offloading shares at the moment, but there are regular A trades buying up shares at around 62.
I don't know why they would be offloading in advance of stellar results, but they may have bought in at a much lower price and taking profits.
On top of this we have the macro economic uncertainty (Ukrain + +) so people are moving to cash.
I cannot see any reason to worry personally, as EKF seem sound and have a good fwd strategy.
One of the few shares I hold now, I have opted for cash now until the macro economic volatility subsides,
seemed like a strong trading update - so why the drop? Puzzling?
Why the drop - update seemed OK
Good update.
In my opinion companies that have benefited from C-19 must show their intention to invest in their core brands and open up new channels.
EKF are showing intent to do this and I have every confidence that they will.
Agreed. Great to see EKF trading - once again - ahead of already upgraded expectations.
With around £20m net cash there's also plenty of headroom for further investment into growth areas and perhaps more acquisitions.
“EKF Diagnostics Holdings plc (AIM: EKF), the?AIM listed point-of-care, central lab devices and chemistry reagents business, confirms that continued strong trading will result in its performance for the financial year ended 31 December 2021, including adjusted EBITDA, being ahead of already upgraded market expectations.”
Very satisfactory. COVID testing is not going away anytime soon but clearly EKF are also strategically diversifying their service offerings to increase the number of revenue streams. All good imo.
A little surprised no Trading Update out yet. Has to be imminent. Am expecting something in the blockbuster category.
Trading update last year on 12th Jan and so would think another incoming this month. Given acquisitions last year, will be very interesting to see.
Not too long to wait now before the next instalment………
“The Board is very confident that trading for the year ending 31 December 2021 will be comfortably ahead of already materially upgraded management expectations.”
Looks like a very solid appointment to me.
https://www.flexicare.com/
Https://www.labmedica.com/molecular-diagnostics/articles/294790533/ekf-diagnostics-showcases-stat-site-wb--ketone-and-glucose-handheld-analyzer-live--in-person-at-medica-2021.html
"EKF Diagnostics Showcases STAT-Site WB ß-ketone and Glucose Handheld Analyzer Live & in Person at MEDICA 2021
By LabMedica International staff writers
Posted on 15 Nov 2021
EKF Diagnostics (Cardiff, Wales, UK) showcased its recently launched STAT-Site WB ß-ketone and glucose handheld analyzer at this year’s MEDICA, the world's largest medical trade fair for medical technology, electromedical equipment, laboratory equipment, diagnostics and pharmaceuticals....
....MEDICA 2021 became the venue for the first public viewing of the new STAT-Site WB ß-ketone and glucose handheld analyzer in Europe since its global launch earlier this year. The STAT-Site WB analyzer from EKF is used for the quantitative determination of ß-ketones (Beta-Hydroxybutyrate or ß-HB) and glucose in whole blood taken from capillary or venous samples. The STAT-Site WB analyzer uses two different strips to provide results in just ten seconds for ß-ketones and five seconds for glucose allowing for clear and comprehensive management of diabetes patients displaying early symptoms of ketosis to be quickly treated and then monitored on a regular basis.
EKF also demonstrated its globally successful PrimeStore MTM (Molecular Transport Medium) molecular transport media that gives the user a “snapshot” in time for that sample by preserving and stabilizing DNA and RNA. PrimeStore MTM was designed and optimized for molecular testing allowing pathogenic samples to be collected, transported, and processed safely and efficiently. The molecular transport medium inactivates infectious biological pathogens including viruses, and gram-positive/negative bacteria whilst preserving and stabilizing labile DNA and RNA for downstream molecular applications.
In addition to PrimeStore MTM, EKF also demonstrated new product innovations relating to the future control of COVID-19, including the COVID-SeroKlir SARS-CoV-2 IgG antibody IVD kit. The Kantaro COVID-SeroKlir kit is a direct ELISA for the quantitative detection of human IgG antibodies to the SARS-CoV-2 virus in serum and plasma (K2-EDTA/Li-Heparin) samples. COVID-SeroKlir is a two-step enzyme-linked immunosorbent assay (ELISA) and can be used by any certified laboratory without the need for proprietary equipment."
Nice plug on Citywire:
Https://citywire.co.uk/funds-insider/news/expert-view-sainsburys-greggs-aston-martin-ekf-and-electrocomponents/a1578341?ref=citywire-money-latest-news-list#i=5
"EKF Diagnostics tests positive for growth
Windfall profits at EKF Diagnostics (EKF) are being reinvested back into the business to build a broader proposition, says Sanford DeLand manager Keith Ashworth-Lord.
Citywire AA-rated Ashworth-Lord holds a position in the diagnostics group through his £127m CFP SDL Free Spirit fund, and said it had reported an ‘excellent set of interims’ that saw sales increase 47% and operating profit up 72%.
‘The core point-of-care diagnostics business is returning to pre-pandemic levels while Covid-19 testing demand remains strong,’ he said.
‘Encouragingly, these windfall profits are being reinvested into building a much broader contract manufacturing and molecular diagnostics business to serve non-Covid-19 related demand.’
Lord said the expansion was customer-led as ‘EKF’s large private sector partner increasingly moves into healthcare’. Meanwhile, in the US, the acquisition of testing laboratory ADL Health is ‘strategically important as it positions EKF as a single provider able to encompass all products and services from sample-to-result’."
Yes they are locked in for 12 months.
Good news - an earnings-enhancing $10m acquisition of a Texas-based lab. The ambitions of the acquiree are clear to see - the deferred consideration is capped at a whopping $60m based on huge and immediate growth, and the vendors are taking an all-share purchase consideration and are locked in for two years:
https://uk.advfn.com/stock-market/london/ekf-diagnostics-EKF/share-news/EKF-Diagnostics-Holdings-PLC-Acquisition-of-Advanc/86147872
Interesting news today. Be interesting to see what value this adds longer term. Company has only been around for a year.